New triple therapy aims to wipe out mantle cell lymphoma

NCT ID NCT07257510

Recruiting now Disease control Sponsor: Peking University Third Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a combination of three drugs—pomalidomide, orelabrutinib, and zuberitamab—in people with untreated mantle cell lymphoma, a type of blood cancer. The goal is to see if the treatment can reduce cancer cells to undetectable levels after six cycles. Participants who achieve this will continue on two of the drugs for maintenance. The trial is currently recruiting 34 patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pomalidomide, orelabrutinib, and zuberitamab
What this could lead to: If successful, this combination could offer a new, effective first-line treatment for mantle cell lymphoma that helps patients achieve undetectable cancer levels.
What could go wrong: This is a small, early-phase trial with only 34 participants, so results may not apply to everyone. The drug combination may cause side effects or fail to control the cancer long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA (MCL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mantle cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MANTLE CELL LYMPHOMA (MCL) POZ

Contacts and locations

Locations

Peking University Third Hospital
RECRUITING

Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.